is nsp csl's swallowing target?

CSL Limited is keep expanding its plasma fractionation services into Asian market, recent plasma-derived therapies sales reached $433 million pa. nearly 20% of the 2B asia market share.

With more and more companies/govs are interested/investing on NSP's PRIME, I donot think CSL can endure NSP, a compatriot MC 8m company to compete with it by expanding plasma fractionation operation in several Asian countries at same time.

For CSL, NSP's established good relation with Singapore gov, received support from Singapore gov alone, already worth much more than multiple of $8m.

I am interested to see if CSL is NSP's first bidder!

quote from CSL report:

"Demand for our plasma fractionation services remains strong and this year we renewed our manufacturing agreement with the New Zealand Blood Service. We also continued to provide plasma fractionation services from our Broadmeadows facility to Hong Kong, Malaysia, Singapore and Taiwan.

Our Asian business again grew well underpinned by demand for albumin in China and by relationships built with distributors in the Asian region for plasma-derived therapies."